Quote | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
Last: | $30 |
---|---|
Change Percent: | 0.3% |
Open: | $30.33 |
Close: | $30 |
High: | $30.33 |
Low: | $29.12 |
Volume: | 515,253 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...
2024-06-24 10:56:01 ET More on Harmony Biosciences Harmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade) Harmony Biosciences Holdings, Inc (HRMY) Q1 2024 Earnings Call Transcript Harmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call...
Message Board Posts | Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
Harmony Biosciences Holdings Inc. Website:
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and ol...
2024-06-21 16:15:08 ET Citigroup analyst issues UNDERPERFORM recommendation for HRMY on June 21, 2024 01:00PM ET. The previous analyst recommendation was Underperform. HRMY was trading at $29.96 at issue of the analyst recommendation. The overall analyst consensus : BUY....